Annexon Submits European Marketing Application for First Targeted Treatment for Guillain-Barré Syndrome

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - Annexon (NASDAQ:ANNX)

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it h…

Annexon Submits European Marketing Application for First Targeted Treatment for Guillain-Barré Syndrome

Annexon has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart for the treatment of Guillain-Barré syndrome (GBS). Annexon is the developer of vonaprument, which is in phase 3 development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). Vonaprument is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally i…